{"transactions":[{"id":751411,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-03T21:24:25.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":51189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Scheduled to vest in four substantially equal quarterly installments."}],"balance_after":51189,"derivative":{"exercise_price":5.84,"expiration_date":"2036-06-01","underlying":"Voting Common Shares","underlying_shares":51189},"source":{"system":"sec-edgar","filing":"0001759855-26-000004","document":"form4-06032026_090621.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000175985526000004/form4-06032026_090621.xml","form_type":"4"}},{"id":752507,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-03T20:30:37.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-26-027089","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027089/ownership.xml","form_type":"4"}},{"id":844372,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-03-13T12:00:03.000Z","date":"2026-03-11","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":1.03,"value":10300.0,"ownership":{"direct":true},"balance_after":41849,"source":{"system":"sec-edgar","filing":"0001493152-26-009983","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226009983/ownership.xml","form_type":"4"}},{"id":946162,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T22:24:34.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":10095,"price":8.42,"value":84999.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $85,000. The deferred stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026."}],"balance_after":97949,"source":{"system":"sec-edgar","filing":"0001759855-26-000002","document":"form4-01062026_100130.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000175985526000002/form4-01062026_100130.xml","form_type":"4"}},{"id":988553,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-25T21:30:55.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents the conversion of the exercise price from CAD$ to US$ on the transaction date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":2.2,"expiration_date":"2025-12-01","underlying":"Common Shares","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001759855-25-000006","document":"form4-11252025_091152.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000175985525000006/form4-11252025_091152.xml","form_type":"4"}},{"id":988552,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-25T21:30:55.000Z","date":"2025-11-21","kind":"exercise","planned":false,"acquired":true,"shares":12000,"price":2.2,"value":26400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the conversion of the exercise price from CAD$ to US$ on the transaction date."}],"balance_after":87854,"source":{"system":"sec-edgar","filing":"0001759855-25-000006","document":"form4-11252025_091152.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000175985525000006/form4-11252025_091152.xml","form_type":"4"}},{"id":1124620,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2025-06-03T20:17:39.000Z","date":"2025-06-01","kind":"grant","planned":false,"acquired":true,"shares":40739,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests in four nearly equal quarterly installments over one year."}],"balance_after":40739,"derivative":{"exercise_price":4.11,"expiration_date":"2035-05-31","underlying":"Common Shares","underlying_shares":40739},"source":{"system":"sec-edgar","filing":"0001437749-25-019293","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000143774925019293/rdgdoc.xml","form_type":"4"}},{"id":1314221,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T21:46:35.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":4287,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vests in two nearly equal installments on each of March 1, 2025 and June 1, 2025."}],"balance_after":4287,"derivative":{"exercise_price":5.51,"expiration_date":"2035-01-01","underlying":"Common Shares","underlying_shares":4287},"source":{"system":"sec-edgar","filing":"0001235802-25-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580225000005/primary_doc.xml","form_type":"4"}},{"id":1314220,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Shares, no par value per share","published_at":"2025-01-03T21:46:35.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":15917,"price":5.34,"value":84996.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are issuable upon vesting and settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $85,000.  The deferred stock units will vest in four nearly equal installments on each of March 31, 2025, June 30, 2025, September 30, 2025 and December 31, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 69,754 shares issuable upon vesting and settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time."}],"balance_after":75854,"source":{"system":"sec-edgar","filing":"0001235802-25-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580225000005/primary_doc.xml","form_type":"4"}},{"id":1494973,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-03T20:21:16.000Z","date":"2024-06-01","kind":"grant","planned":false,"acquired":true,"shares":28472,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests in four nearly equal quarterly installments over one year."}],"balance_after":28472,"derivative":{"exercise_price":2.9,"expiration_date":"2034-05-31","underlying":"Common Shares","underlying_shares":28472},"source":{"system":"sec-edgar","filing":"0001235802-24-000047","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580224000047/primary_doc.xml","form_type":"4"}},{"id":1696365,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Shares, no par value per share","published_at":"2024-01-02T21:39:36.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":21428,"price":2.8,"value":59998.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $60,000."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 53,837 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan."}],"balance_after":59937,"source":{"system":"sec-edgar","filing":"0001235802-24-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580224000002/primary_doc.xml","form_type":"4"}},{"id":1869420,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:21:07.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":16968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests in four nearly equal quarterly installments over one year."}],"balance_after":16968,"derivative":{"exercise_price":2.73,"expiration_date":"2033-05-31","underlying":"Common Shares","underlying_shares":16968},"source":{"system":"sec-edgar","filing":"0001235802-23-000058","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580223000058/primary_doc.xml","form_type":"4"}},{"id":2247263,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-02T20:44:27.000Z","date":"2022-06-01","kind":"grant","acquired":true,"shares":13222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests in four nearly equal quarterly installments over one year."}],"balance_after":13222,"derivative":{"exercise_price":2.45,"expiration_date":"2032-05-31","underlying":"Common Shares","underlying_shares":13222},"source":{"system":"sec-edgar","filing":"0001235802-22-000072","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580222000072/primary_doc.xml","form_type":"4"}},{"id":2454050,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Shares, no par value per share","published_at":"2022-01-03T21:21:31.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":16773,"price":3.58,"value":60047.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $60,000."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount reflects the cancellation of 211 shares underlying deferred share units granted in lieu of Board committee retainers due to a change in Board committee memberships."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 32,409 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan."}],"balance_after":38509,"source":{"system":"sec-edgar","filing":"0001235802-22-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580222000002/primary_doc.xml","form_type":"4"}},{"id":2502231,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:29:14.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":30171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The exercise price of these options is $19.333 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":15.27,"expiration_date":"2025-11-19","underlying":"Common Shares","underlying_shares":30171},"source":{"system":"sec-edgar","filing":"0001104659-21-141747","document":"tm2133436-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141747/tm2133436-5_4seq1.xml","form_type":"4"}},{"id":2502230,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:29:14.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":30171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of these options is $13.98 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":11.04,"expiration_date":"2026-05-27","underlying":"Common Shares","underlying_shares":30171},"source":{"system":"sec-edgar","filing":"0001104659-21-141747","document":"tm2133436-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141747/tm2133436-5_4seq1.xml","form_type":"4"}},{"id":2502229,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:29:14.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":24390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The exercise price of these options is $12.22 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":9.65,"expiration_date":"2027-11-09","underlying":"Common Shares","underlying_shares":24390},"source":{"system":"sec-edgar","filing":"0001104659-21-141747","document":"tm2133436-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141747/tm2133436-5_4seq1.xml","form_type":"4"}},{"id":2502228,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:29:14.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":36204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price of these options is $10.35 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":8.18,"expiration_date":"2024-04-17","underlying":"Common Shares","underlying_shares":36204},"source":{"system":"sec-edgar","filing":"0001104659-21-141747","document":"tm2133436-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141747/tm2133436-5_4seq1.xml","form_type":"4"}},{"id":2502227,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:29:14.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":5761,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price of these options is $9.20 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":7.27,"expiration_date":"2026-11-09","underlying":"Common Shares","underlying_shares":5761},"source":{"system":"sec-edgar","filing":"0001104659-21-141747","document":"tm2133436-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141747/tm2133436-5_4seq1.xml","form_type":"4"}},{"id":2502226,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:29:14.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":59896,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price of these options is $4.23 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":3.34,"expiration_date":"2028-11-08","underlying":"Common Shares","underlying_shares":59896},"source":{"system":"sec-edgar","filing":"0001104659-21-141747","document":"tm2133436-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141747/tm2133436-5_4seq1.xml","form_type":"4"}},{"id":2502225,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:29:14.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":94792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":0.3,"expiration_date":"2029-11-07","underlying":"Common Shares","underlying_shares":94792},"source":{"system":"sec-edgar","filing":"0001104659-21-141747","document":"tm2133436-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141747/tm2133436-5_4seq1.xml","form_type":"4"}},{"id":2502224,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-19T13:29:14.000Z","date":"2021-11-17","kind":"disposition_to_issuer","acquired":false,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On November 17, 2021 (the \"Closing Date\"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the \"Purchaser\") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the \"Issuer\") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the \"Plan of Arrangement\"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the \"Effective Time\") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash."}],"balance_after":0,"derivative":{"exercise_price":12.03,"expiration_date":"2030-12-23","underlying":"Common Shares","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001104659-21-141747","document":"tm2133436-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000110465921141747/tm2133436-5_4seq1.xml","form_type":"4"}},{"id":2631889,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option  (right to buy)","published_at":"2021-07-16T20:45:23.000Z","date":"2021-07-15","kind":"grant","acquired":true,"shares":9393,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests in four nearly equal quarterly installments over one year."}],"balance_after":9393,"derivative":{"exercise_price":3.64,"expiration_date":"2031-07-14","underlying":"Common Shares","underlying_shares":9393},"source":{"system":"sec-edgar","filing":"0001235802-21-000081","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580221000081/primary_doc.xml","form_type":"4"}},{"id":2909070,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-12T16:12:49.000Z","date":"2021-01-08","kind":"exercise","acquired":false,"shares":8505,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price of these options is $9.20 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7875 USD."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months."}],"balance_after":5761,"derivative":{"exercise_price":7.2447,"expiration_date":"2026-11-09","underlying":"Common Shares","underlying_shares":8505},"source":{"system":"sec-edgar","filing":"0001062993-21-000293","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321000293/form4.xml","form_type":"4"}},{"id":2909069,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2021-01-12T16:12:49.000Z","date":"2021-01-08","kind":"sale","acquired":false,"shares":8505,"price":15.7873,"value":134270.9865,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.74 to $15.90 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001062993-21-000293","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321000293/form4.xml","form_type":"4"}},{"id":2909068,"issuer":{"id":133265,"kind":"organization","name":"Trillium Therapeutics Inc.","symbol":"TRIL"},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2021-01-12T16:12:49.000Z","date":"2021-01-08","kind":"exercise","acquired":true,"shares":8505,"price":7.2447,"value":61616.1735,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The exercise price of these options is $9.20 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.7875 USD."}],"balance_after":8505,"source":{"system":"sec-edgar","filing":"0001062993-21-000293","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1616212/000106299321000293/form4.xml","form_type":"4"}},{"id":2925378,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Shares, no par value per share","published_at":"2021-01-04T21:21:19.000Z","date":"2021-01-01","kind":"grant","acquired":true,"shares":7745,"price":8.23,"value":63741.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $63,750."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 15,847 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan."}],"balance_after":21947,"source":{"system":"sec-edgar","filing":"0001235802-21-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580221000002/primary_doc.xml","form_type":"4"}},{"id":3126744,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-02T20:49:12.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":13306,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Vests in four nearly equal quarterly installments over one year."}],"balance_after":13306,"derivative":{"exercise_price":4.64,"expiration_date":"2030-05-31","underlying":"Common Shares","underlying_shares":13306},"source":{"system":"sec-edgar","filing":"0001235802-20-000050","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580220000050/primary_doc.xml","form_type":"4"}},{"id":3126743,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Shares, no par value per share","published_at":"2020-06-02T20:49:12.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":8102,"price":4.59,"value":37188.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan in lieu of cash retainer fees in the aggregate amount of $37,188."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan."}],"balance_after":14202,"source":{"system":"sec-edgar","filing":"0001235802-20-000050","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580220000050/primary_doc.xml","form_type":"4"}},{"id":3477982,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-26T20:36:38.000Z","date":"2019-06-24","kind":"grant","acquired":true,"shares":12950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Vests in four nearly equal quarterly installments over one year."}],"balance_after":12950,"derivative":{"exercise_price":4.6,"expiration_date":"2029-06-23","underlying":"Common Shares","underlying_shares":12950},"source":{"system":"sec-edgar","filing":"0001235802-19-000063","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580219000063/primary_doc.xml","form_type":"4"}},{"id":3735339,"issuer":{"id":5813,"kind":"organization","name":"DiaMedica Therapeutics Inc."},"owners":[{"id":41696,"kind":"person","name":"Parsons James T.","position":1,"cik":"0001759855","reported_name":"Parsons James T.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Shares, no par value per share","published_at":"2018-12-11T21:27:15.000Z","date":"2018-12-11","kind":"purchase","acquired":true,"shares":2250,"price":4,"value":9000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan."}],"balance_after":6100,"source":{"system":"sec-edgar","filing":"0001235802-18-000181","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1401040/000123580218000181/primary_doc.xml","form_type":"4"}}]}